Baldwin Brothers Inc. MA reduced its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 13.8% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 11,845 shares of the medical equipment provider’s stock after selling 1,900 shares during the quarter. Baldwin Brothers Inc. MA’s holdings in Zimmer Biomet Holdings were worth $1,387,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ZBH. Bronfman E.L. Rothschild L.P. increased its holdings in Zimmer Biomet Holdings by 25.3% during the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 827 shares of the medical equipment provider’s stock worth $106,000 after purchasing an additional 167 shares during the period. Parkside Financial Bank & Trust increased its holdings in Zimmer Biomet Holdings by 3.9% during the 2nd quarter. Parkside Financial Bank & Trust now owns 872 shares of the medical equipment provider’s stock worth $112,000 after purchasing an additional 33 shares during the period. Parallel Advisors LLC increased its holdings in Zimmer Biomet Holdings by 20.8% during the 1st quarter. Parallel Advisors LLC now owns 1,157 shares of the medical equipment provider’s stock worth $138,000 after purchasing an additional 199 shares during the period. IHT Wealth Management LLC increased its holdings in Zimmer Biomet Holdings by 28.4% during the 1st quarter. IHT Wealth Management LLC now owns 1,158 shares of the medical equipment provider’s stock worth $139,000 after purchasing an additional 256 shares during the period. Finally, BB&T Investment Services Inc. purchased a new position in Zimmer Biomet Holdings during the 2nd quarter worth $144,000. Institutional investors own 85.26% of the company’s stock.
ZBH has been the topic of several research reports. Zacks Investment Research downgraded Zimmer Biomet Holdings from a “hold” rating to a “sell” rating in a report on Tuesday, July 4th. BMO Capital Markets restated a “buy” rating and set a $136.00 price objective on shares of Zimmer Biomet Holdings in a report on Tuesday, July 11th. Wells Fargo & Company restated a “market weight” rating on shares of Zimmer Biomet Holdings in a report on Friday, July 14th. Morgan Stanley increased their target price on Zimmer Biomet Holdings from $137.00 to $150.00 and gave the company an “overweight” rating in a research report on Monday, July 17th. Finally, Stifel Nicolaus reaffirmed a “hold” rating and set a $125.00 target price on shares of Zimmer Biomet Holdings in a research report on Friday, July 14th. Three analysts have rated the stock with a sell rating, eight have given a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $136.55.
COPYRIGHT VIOLATION WARNING: This story was published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The correct version of this story can be viewed at https://www.com-unik.info/2017/10/30/baldwin-brothers-inc-ma-trims-holdings-in-zimmer-biomet-holdings-inc-zbh.html.
Shares of Zimmer Biomet Holdings, Inc. (ZBH) traded down 1.87% during mid-day trading on Monday, reaching $122.13. The company’s stock had a trading volume of 231,678 shares. The company’s 50-day moving average is $117.99 and its 200-day moving average is $120.43. Zimmer Biomet Holdings, Inc. has a 52 week low of $95.63 and a 52 week high of $133.49. The stock has a market capitalization of $24.69 billion, a price-to-earnings ratio of 34.78 and a beta of 1.19.
Zimmer Biomet Holdings (NYSE:ZBH) last released its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $2.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.10 by ($0.02). Zimmer Biomet Holdings had a net margin of 9.12% and a return on equity of 16.70%. The company had revenue of $1.95 billion during the quarter, compared to analyst estimates of $1.95 billion. During the same quarter in the prior year, the company earned $2.02 EPS. The business’s revenue was up 1.1% on a year-over-year basis. Equities analysts predict that Zimmer Biomet Holdings, Inc. will post $8.23 EPS for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Friday, October 27th. Shareholders of record on Friday, September 22nd were paid a $0.24 dividend. The ex-dividend date was Thursday, September 21st. This represents a $0.96 annualized dividend and a yield of 0.77%. Zimmer Biomet Holdings’s dividend payout ratio is presently 27.59%.
Zimmer Biomet Holdings Company Profile
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
What are top analysts saying about Zimmer Biomet Holdings Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Zimmer Biomet Holdings Inc. and related companies.